Navigation Links
Pharmaceutical Giant AstraZeneca to Pay $520 Million for Off-Label Drug Marketing
Date:4/27/2010

h 2006, AstraZeneca brought certain conduct to the attention of the government and then cooperated in the investigation of the allegations being settled today.

The United States contends that AstraZeneca promoted the unapproved uses by improperly and unduly influencing the content of, and speakers, in company-sponsored continuing medical education programs. The company also engaged doctors to give promotional speaker programs on unapproved uses for Seroquel and to conduct studies on unapproved uses of Seroquel.  In addition, the company recruited doctors to serve as authors of articles that were ghostwritten by medical literature companies and about studies the doctors in question did not conduct.  AstraZeneca then used those studies and articles as the basis for promotional messages about unapproved uses of Seroquel.

"Illegal acts by pharmaceutical companies and false claims against Medicare and Medicaid can put the public health at risk, corrupt medical decisions by health care providers, and take billions of dollars directly out of taxpayers' pockets," said Attorney General Eric Holder.  "This Administration is committed to recovering taxpayer money lost to health care fraud, whether it's by bringing cases against common criminals operating out of vacant storefronts or executives at some of the nation's biggest companies."

The United States also contends that AstraZeneca violated the federal Anti-Kickback Statute by offering and paying illegal remuneration to doctors it recruited to serve as authors of articles written by AstraZeneca and its agents about the unapproved uses of Seroquel.  AstraZeneca also offered and paid illegal remuneration to doctors to travel to resort locations to "advise" AstraZeneca about marketing messages for unapproved us
'/>"/>

SOURCE U.S. Department of Justice
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... , Oct. 2, 2014   West Pharmaceutical ... global leader in innovative solutions for injectable drug administration, ... operations to include a new site in ... packaging components for insulin injector cartridges and other high-value ... pharmaceutical and biotech customers. Once operational, this new site ...
(Date:10/1/2014)... , Oct. 1, 2014   Plexus ... provider of Anesthesia Information Management Systems (AIMS), announced ... LLC , a wholly owned subsidiary of Quality ... information systems and connectivity solutions.  ... http://photos.prnewswire.com/prnh/20140930/149407 This partnership extends ...
(Date:10/1/2014)... NeuroCall, Inc., ("NeuroCall") announced today that it recently received ... Dr. Ricardo Garcia-Rivera , Founder and Chief Medical ... our quality of service has been recognized by The ... and continuity of care to patients of our expanding ... States ." NeuroCall currently provides ...
Breaking Medicine Technology:West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 2West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 3West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 4West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 5Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3NeuroCall Awarded Joint Commission Accreditation 2
... , MINNEAPOLIS , Feb. 4 ... of state-of-the-art cardiac surgery products and services, today announced that it will ... , after the market close on Monday, March 1, 2010 . ... March 1, 2010 at 5:00 p.m. Eastern Time ( ...
... PITTSBURGH , Feb. 4 Mylan Inc. (Nasdaq: ... in connection with the filing of an Abbreviated New Drug Application ... Besylate and Atorvastatin Calcium Tablets 2.5/10 mg, 2.5/20 mg, 2.5/40 mg, ... mg, 10/40 and 10/80 mg. This product is the generic version ...
Cached Medicine Technology:ATS Medical Announces Fourth Quarter 2009 Earnings Release Date and Conference Call 2ATS Medical Announces Fourth Quarter 2009 Earnings Release Date and Conference Call 3Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R) 2
(Date:10/2/2014)... October 02, 2014 Robins & ... the Associated Builders and Contractors (ABC) of Alabama. ... tonight’s banquet held at Sheraton Birmingham Hotel., ... Healthcare $10 Million to $25 Million, Obelisk Award ... Clinic, Federal Government $10 Million to $25 Million, ...
(Date:10/2/2014)... Maureen Salamon ... News) -- Middle-aged women with a neurotic personality style ... developing Alzheimer,s disease, new research suggests. Tracking 800 ... those who were most anxious, jealous and moody -- ... stress had double the risk of developing Alzheimer,s compared ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 ... isn,t reduced by breast-feeding. Nor will delaying the introduction of ... diet help prevent celiac disease. Those are the ... 2 New England Journal of Medicine . The ... avoid celiac disease if mothers breast-feed their babies and introduce ...
(Date:10/1/2014)... of Adelaide have developed a model that could help ... from treatment - from their very first psychotic episode. ... factors, including clinical symptoms, cognitive abilities, MRI scans of ... , Speaking in the lead up to World Mental ... Psychiatry , Professor Bernhard Baune , says the ...
(Date:10/1/2014)... co-funded by the Engineering and Physical Sciences Research ... the UK,s vital industrial control systems which run, ... grid, and the rail network. , The ... hackers or malware infiltrating the systems behind our ... in Trustworthy Industrial Control Systems (RITICS), based at ...
Breaking Medicine News(10 mins):Health News:Robins & Morton wins nine awards from Associated Builders and Contractors 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 3Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 3Health News:Predicting the future course of psychotic illness 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2
... new study in the Annals,of Internal Medicine adds ... patients for the bacterium MRSA (methicillin-resistant,Staphylococcus aureus) is ... The study, published yesterday, resulted in a 70%,reduction ... in the,Evanston Northwestern Healthcare System, located near Chicago., ...
... 2008, WASHINGTON, March 18 Following is the,National ... The Bulletin, which is free of charge and available ... the latest issues and news,affecting people with disabilities. To ... click on Online mailing list archives,select NCD-NEWS-L, click on ...
... One of the nations oldest and most respected non-profit ... fellowships to underrepresented minority students and scientists to attend ... 5-9. The American Physiological Society (APS), which administers the ... travel awards. , APS administers the program with financial ...
... and SHANGHAI, China, March 18 ,Flagship Global Health, ... Limited (CHC), listed on the Stock Exchange of ... a strategic alliance to,jointly utilize their resources and ... leading insurance companies, including,China Ping An and China ...
... safety tests and is relatively painless , , TUESDAY, March 18 ... veins proved safe in patients, according to the results of ... found that use of injectable Varisolve microfoam didn,t cause any ... patients with a common heart defect. , Since 1997, ...
... HILL, N.C., March 18 The Internet has ... leaders,haven,t lost sight of the value of an ... a relationship and high performing sales,groups -- irrespective ... of their time identifying and addressing existing clients, ...
Cached Medicine News:Health News:Evanston-Northwestern Study Proves Effectiveness of MRSA Screening to Reduce Hospital Infections 2Health News:National Council on Disability Monthly Bulletin for February, 2008 2Health News:National Council on Disability Monthly Bulletin for February, 2008 3Health News:National Council on Disability Monthly Bulletin for February, 2008 4Health News:52 minority scientists receive travel fellowships to Experimental Biology 2008 2Health News:52 minority scientists receive travel fellowships to Experimental Biology 2008 3Health News:Flagship Global Health and China HealthCare Holdings Form Strategic Alliance 2Health News:Flagship Global Health and China HealthCare Holdings Form Strategic Alliance 3Health News:New Foam Treatment for Varicose Veins 2Health News:High Performing Sales Forces Follow Same Path to Excellence 2
AST (SGOT) R1 + R2. Automated analyzer test kits....
Intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma. Reaction: Kinetic. Wavelength: 340 nm. Linearity: 268 U/L at 30C. Two vials, dry powder reagents...
The Midas II Stainer is an automated slide stainer designed for use in hematology and microbiology laboratories....
... TST 40 tissue stainer is an "assembly-line ... in histology and cytology laboratories. Programmable continuous ... stains big quantities of slides in short ... in combination with a continuous working principle ...
Medicine Products: